MedTrace Logo

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03487276 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2021-04-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

DRUG

IFX-1

Single IV infusions of IFX-1 diluted in sodium chloride.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • InflaRx GmbH

    lead INDUSTRY

Principal Investigators

  • Othmar Zenker, CMO · InflaRx GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-26
Primary Completion
2019-05-27
Completion
2020-01-27
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Denmark
  • France
  • Germany
  • Greece
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03487276 on ClinicalTrials.gov